Verde Science Adds John M. E. Percival to the Head of
Strategic Development and member of Board of Directors
LAS VEGAS, NV -- May 4, 2015 -- InvestorsHub NewsWire --
(OTCPK:
VRCI) Verde Science, Inc. a Pharmaceutical Research and
Development Company focused on developing a portfolio of
cannabinoid based prescription medicines to meet patients needs for
a wide range of medical conditions is pleased to announce the
appointment of John M. E. Percival to its Board of Directors and
Head of Strategic Business Development. Mr. Percival brings
over 20 years of Investment Banking, Corporate Finance and
Strategic planning success to Verde. Mr. Percival was previously
General Manager of Investments at Barclays Bank New Zealand, Ltd
where he was responsible for the management of nearly a $500
million in Superannuation and private funds.
Mr. Percival commented, “I am extremely excited to be asked to
join the Board of Directors of Verde Science. My assessment
of the nascent medical marijuana space convinces me of the
attractiveness of the Verde Science pharmacological approach to
harness the healing powers of the medical marijuana plant and aid
the company in its pathway to bring medicine to market. I
look forward to being an active participant in the growth of Verde
and the attainment of its goals for the improvement of health care
treatment throughout the world and particularly in Australia where
the Queensland Government has recently announced a significant
program to research the benefits of medical marijuana.”
Verde Science CEO, Harp Sangha offered, “I am delighted with the
addition of John Percival . John brings a pristine record of
success and believe he will be highly effective resource and
rainmaker for the company’
About Verde Science, Inc. (PINKSHEETS:VRCI)
Verde Science, Inc. (trading symbol PINKSHEETS:VRCI)
is an early stage pharmaceutical organization that has built a
research team focused on developing a portfolio of cannabinoid
prescription medicines to meet patient needs in a wide range of
medical conditions. Verde's scientists have identified a number of
promising areas in which to begin its immediate R&D program,
which will initially be based in India. The Verde Science team of
inter-disciplinary researchers includes scientists in Bioprocess
Engineering, Nanotechnology, Molecular Biology, Pharmaceutical
Sciences and Bio-Medical Devices that is focused on a streamlined
approach to the development of innovative treatment protocols aimed
at capturing considerable market share.
Contact Info :
www.verdescienceinc.com
Louis Silver, Director of Investor Relations
Tel: 1-610-710-1303
lsilver@verdescienceinc.com
Safe Harbor Statements
Certain information contained in this news release constitutes
“forward-looking statements” as such term is used in applicable
United States and Canadian laws. Generally, these forward-looking
statements can be identified by the use of forward-looking
terminology such as “expects” or “does not expect”, “is expected”,
“anticipates” or “does not anticipate”, “plans”, “estimates”,
“intends” or “believes”, or that certain actions, events or results
“may”, “could”, “would”, “might” or “will be taken”, “occur”, or
“be achieved”. Forward-looking statements are based on the
opinions and estimates of management as of the date such statements
are made, and are subject to known and unknown risks, uncertainties
and other factors that may cause the actual results, performance or
achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements. Many of
these factors are beyond the Company’s ability to control or
predict. Important factors that may cause actual results to differ
materially and that could impact the Company and the statements
contained in this news release can be found in the Company’s
filings with the SEC. Such risks and other factors include, among
others, the ability to locate and acquire suitable interests in
alternative medicine manufacturing operations on terms acceptable
to the Company, the availability of financing on acceptable terms,
accidents, labor disputes, acts of God and other risks of the
alternative medicine industry including, without limitation, delays
in obtaining governmental approvals or permits, title disputes or
claims limitations on insurance coverage. The Company believes that
the expectations reflected in the forward-looking statements
included in this news release are reasonable; however, no assurance
can be given that these expectations will prove to be correct, and
such forward-looking statements should not be unduly relied upon.
The Company assumes no obligation to update or supplement any
forward-looking statements whether as a result of new information,
future events or otherwise